Skip to main content
Log in

The Disease-Modifying Effects of Twice-Weekly Oral Azithromycin in Patients with Bronchiectasis

  • Brief Communication
  • Published:
Treatments in Respiratory Medicine

Abstract

Introduction

Bronchiectasis is a chronic pulmonary process characterized by recurrent respiratory infections leading to destruction of airways secondary to inflammation. We investigated whether the addition of 6-months’ twice-weekly azithromycin to the existing treatment regimen in patients with pulmonary bronchiectasis decreased the number of exacerbations and improved pulmonary function compared with a similar period of time without concurrent azithromycin.

Methods

Thirty patients with high-resolution computed tomography scan-confirmed bronchiectasis were to be recruited. In random order, patients received usual medications for 6 months, and usual medications plus oral azithromycin 500mg twice weekly for 6 months. Patients receiving azithromycin first had a 1-month washout period prior to entering the second phase. Patients recorded weekly peak flow (PF) measurements. Pulmonary function tests (PFTs), 24-hour sputum volume, and needs for intervention with medication or ancillary support were collected at baseline and every 3 months. Exacerbation incidence and sputum volume measurements were compared from baseline to the end of each study phase.

Results

Twelve patients were enrolled; 11 were included in the analysis. Owing to randomization, most patients received the azithromycin first, which was fairly well tolerated. PFTs did not change significantly during either study phase and PFs appeared to remain stable during azithromycin therapy and throughout the subsequent control phase. Azithromycin significantly decreased the incidence of exacerbations compared with usual medications (5 vs 16; p = 0.019). Mean 24-hour sputum volume significantly decreased (15% [p = 0.005]) during the active treatment phase, and remained decreased during the control phase (p = 0.028). Subjectively, patients reported increased energy and quality of life while receiving treatment with azithromycin.

Conclusions

The addition of twice-weekly azithromycin significantly decreased the incidence of exacerbation and 24-hour sputum volume and may have stabilized the PFTs and PFs in this 11-patient pilot study. The results of this study justify further investigation of adding azithromycin to the treatment regimens of patients with bronchiectasis for its disease-modifying effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Nicotra MB, Rivera M, Dale AM, et al. Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort. Chest 1995; 108: 955–61

    Article  PubMed  CAS  Google Scholar 

  2. Barker AF. Bronchiectasis. N Engl J Med 2002; 346: 1383–93

    Article  PubMed  Google Scholar 

  3. Angrill J, Agusti C, De Celis R, et al. Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. Am J Respir Crit Care Med 2001; 164: 1628–32

    PubMed  CAS  Google Scholar 

  4. Nagai H, Shishido H, Yoneda R, et al. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration 1991; 58: 145–9

    Article  PubMed  CAS  Google Scholar 

  5. Kadota J, Sakito O, Kohno S, et al. A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis. Am Rev Respir Dis 1993; 147: 153–9

    Article  PubMed  CAS  Google Scholar 

  6. Fujii T, Kadota J, Kawakami K, et al. Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection. Thorax 1995; 50: 1246–52

    Article  PubMed  CAS  Google Scholar 

  7. Sakito O, Kadota J, Kohno S, et al. Interleukin 1B, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. Respiration 1996; 63: 42–8

    Article  PubMed  CAS  Google Scholar 

  8. Yanagihara K, Tomono K, Sawai T, et al. Effect of clarithromycin on lymphocytes in chronic respiratory Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 1997; 155: 337–42

    PubMed  CAS  Google Scholar 

  9. Kudoh S. Erythromycin treatment in diffuse panbronchiolitis. Curr Opin Pulm Med 1998; 4: 116–21

    Article  PubMed  CAS  Google Scholar 

  10. Jaffe A, Francis J, Rosenthal M, et al. Long-term azithromycin may improve lung function in children with cystic fibrosis [letter]. Lancet 1998; 351: 420

    Article  PubMed  CAS  Google Scholar 

  11. Pirzada OM, Taylor CJ. Long term macrolide antibiotics improve pulmonary function in cystic fibrosis [abstract]. Pediatr Pulmonol 1999; 19 Suppl.: 263

    Google Scholar 

  12. Wolter J, Seeney S, Bowler S, et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002; 57: 212–6

    Article  PubMed  CAS  Google Scholar 

  13. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990; 25Suppl. A: 73–82

    PubMed  CAS  Google Scholar 

  14. Ballow CH, Amsden GW. Azithromycin: the first azalide antibiotic. Ann Pharmacother 1992; 26: 1253–61

    PubMed  CAS  Google Scholar 

  15. Ballow CH, Amsden GW, Forrest A, et al. Pharmacokinetics of oral azithromycin in serum, urine, polymorphonuclear leukocytes and inflammatory versus noninflammatory skin blisters in healthy volunteers. Clin Drug Invest 1998; 15: 159–67

    Article  CAS  Google Scholar 

  16. Amsden GW, Ballow CH, Forrest A. Comparison of the plasma, urine, and blister fluid pharmacokinetics of clarithromycin and azithromycin in normal subjects. Clin Drug Invest 1997; 13: 152–61

    Article  CAS  Google Scholar 

  17. Amsden GW, Nafziger AN, Foulds G. Serum pharmacokinetics and WBC exposures of oral azithromycin 1500mg given over a 3- or 5-day period in healthy subjects. Antimicrob Agents Chemother 1999; 43: 163–5

    PubMed  CAS  Google Scholar 

  18. Pai MP, Graci DM, Amsden GW. Macrolide drug interactions: an update. Ann Pharmacother 2000; 34: 495–513

    Article  PubMed  CAS  Google Scholar 

  19. Tsang KWT, Ho PI, Chan KN, et al. A pilot study of low-dose erythromycin in bronchiectasis. Eur Respir J 1999; 13: 361–4

    Article  PubMed  CAS  Google Scholar 

  20. Koh YY, Lee MH, Sun YH, et al. Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. Eur Respir J 1997; 10: 994–9

    Article  PubMed  CAS  Google Scholar 

  21. Gerhardt SG, McDyer JS, Girgis RE, et al. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2003; 168: 121–5

    Article  PubMed  Google Scholar 

  22. Amayasu H, Yoshida S, Ebana S, et al. Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Ann Allergy Asthma Immunol 2000; 84: 594–8

    Article  PubMed  CAS  Google Scholar 

  23. Morikawa K, Zhang J, Nonaka M, et al. Modulatory effect of macrolide antibiotics on the Th1- and Th2-type cytokine production. Int J Antimicrob Agents 2002; 19: 53–9

    Article  PubMed  CAS  Google Scholar 

  24. Foulds G, Luke DR, Teng R, et al. The absence of an effect of food on the bioavailability of azithromycin administered as tablets, sachet or suspension. J Antimicrob Chemother 1996; 37Suppl. C: 37–4

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Guy W. Amsden.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cymbala, A.A., Edmonds, L.C., Bauer, M.A. et al. The Disease-Modifying Effects of Twice-Weekly Oral Azithromycin in Patients with Bronchiectasis. Treat Respir Med 4, 117–122 (2005). https://doi.org/10.2165/00151829-200504020-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151829-200504020-00005

Keywords

Navigation